Literature DB >> 11374857

Evaluating niacin in its various forms.

R H Knopp1.   

Abstract

Niacin is available in a number of different formulations according to the speed of drug release. The nomenclature is not standardized, and many names are used interchangeably, creating confusion. Formulations that differ in time of release may have different lipid effects and vary in their adverse reaction profiles. Studies comparing immediate-release with various time-release formulations illustrate these variations. Studies have found immediate-release and the intermediate, or extended-release, once-a-day, prescription form of niacin (i.e., Niaspan), to be essentially equivalent with respect to their efficacy in reducing triglycerides and increasing high-density lipoprotein cholesterol (HDL-C). However, there are fewer side effects and better compliance associated with the latter form.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11374857     DOI: 10.1016/s0002-9149(00)01471-5

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  7 in total

1.  Flushing and pruritus secondary to prescription fish oil ingestion in a patient with allergy to fish.

Authors:  Amanda Howard-Thompson; Anna Dutton; Robert Hoover; Jennifer Goodfred
Journal:  Int J Clin Pharm       Date:  2014-10-16

Review 2.  A "hot" topic in dyslipidemia management--"how to beat a flush": optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention.

Authors:  Terry A Jacobson
Journal:  Mayo Clin Proc       Date:  2010-04       Impact factor: 7.616

Review 3.  Prolonged-release nicotinic acid: a review of its use in the treatment of dyslipidaemia.

Authors:  Paul L McCormack; Gillian M Keating
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 4.  Niacin, lipids, and heart disease.

Authors:  Shaista Malik; Moti L Kashyap
Journal:  Curr Cardiol Rep       Date:  2003-11       Impact factor: 2.931

5.  Atherosclerosis regression.

Authors:  Justin M S Lee; Alistair C Lindsay; Ilias Kylintireas; Robin P Choudhury
Journal:  Curr Treat Options Cardiovasc Med       Date:  2008-06

6.  pH-Responsive Inorganic/Organic Nanohybrids System for Controlled Nicotinic Acid Drug Release.

Authors:  Seungjin Yu; Huiyan Piao; N Sanoj Rejinold; Hanna Lee; Goeun Choi; Jin-Ho Choy
Journal:  Molecules       Date:  2022-09-29       Impact factor: 4.927

Review 7.  Niacin-ER/statin combination for the treatment of dyslipidemia: focus on low high-density lipoprotein cholesterol.

Authors:  Steven G Chrysant; Mohammed Ibrahim
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-07       Impact factor: 3.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.